| Document Date: 2010-02-04 16:31:08 Open Document File Size: 563,95 KBShare Result on Facebook
City Sirolimus / / Company CNI / Rapamune / Wyeth Pharmaceuticals Inc. / / Country United States / / Event Product Recall / Product Issues / / IndustryTerm food / continuation / conversion / / MedicalCondition established hyperlipidemia / Nephrotic range proteinuria / lymphoma/lymphoproliferative disease / Lymphoma / headache / Hypersensitivity Reactions Hypersensitivity / Calcineurin Inhibitor-Induced Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura / urinary tract infection / hypersensitivity vasculitis / Skin Cancer / nausea / thrombocytopenia / diarrhea / Hypersensitivity / MS / hepatic artery thrombosis / onset nephrosis / sepsis / lymphedema / pleural effusion / fatal infections / Proteinuria / abdominal pain / hypertension / opportunistic infections / arthralgia / hypertriglyceridemia / Carcinogenesis / Hyperlipidemia / fever / rhabdomyolysis / nephrotic syndrome / pain / Latent Viral Infections / Angioedema / lymphoma and other malignancies / infection / angioedema / exfoliative dermatitis / lymphocele / pericardial effusions / anemia / hypercholesterolemia / Interstitial Lung Disease / tuberculosis / / MedicalTreatment Renal Transplantation / renal transplants / liver transplant / Vaccination / organ transplants / lung transplant / IMMUNOSUPPRESSION / immunosuppressive therapy / organ transplant / dialysis / renal transplant / / Organization DOSAGE AND ADMINISTRATION / FDA / / / Position physician / / Product Cyclosporine / Rapamune / acute rejection / ORAL SOLUTION AND TABLETS / amphotericin B / CsA / Prednisone / azathioprine / Rapamune Following Cyclosporine / prescribed amount of Rapamune Oral Solution / Use Cyclosporine / / Technology drug metabolism / antibodies / transplantation / Pharmacokinetics / Pharmacodynamics / dialysis / / URL www.fda.gov/medwatch / /
SocialTag |